Immunoblot, Chemiluminescence and ImmunoCap Allergen Specific IgE Evaluation of in Allergic Rhinitis Patients
- Conditions
- Diagnoses Disease
- Interventions
- Diagnostic Test: Sensitization to House dust mites
- Registration Number
- NCT06137495
- Lead Sponsor
- Zagazig University
- Brief Summary
In the present study the investigators assay house dust mites (HDMs) IgE in sera of allergic rhinitis patients (AR) using immunoblotting, chemiluminescence, and ImmunoCAP assays to compare between the accuracy of both immunoblotting and chemiluminescence assays, and ImmunoCAP as gold standard.
- Detailed Description
All allergic rhinitits patients who were monosensitized to mixed HDMs, identified by SPT, will be subjected to complete history taking and assessment of the inclusion and exclusion criteria, performance of skin prick test and measurement of total serum IgE, measurement of specific IgE by Chemiluminescence Immunoassa, immunoblot assay and ImmunoCAP™ Phadiatop™. The patients will be followed-up for 6 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 84
- Patient consent.
- Patient with (18-40) years age known to be allergic rhinitis.
- Patient with IgE mediated allergic rhinitis (positive total IgE).
- Patient with positive skin prick testing and monosensitized to HDM
- Patient refusal
- Patients taking oral corticosteroid.
- Patients taking anti-IgE injections.
- Patients taking intranasal corticosteroid.
- Patient with non- IgE mediated allergic rhinitis.
- Patients with chronic diseases.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Allergic Rhinitis Patients Sensitization to House dust mites House dust mites (HDMs) IgE in sera of allergic rhinitis patients (AR) who were monosensitized to mixed HDMs, identified by SPT, is assayed using immunoblotting, chemiluminescence, and ImmunoCAP assays to compare between the accuracy of both immunoblotting and chemiluminescence assays, and ImmunoCAP as gold standard
- Primary Outcome Measures
Name Time Method Reduction of serum specific IgE 6 months from diagnosis to end of Follow-up period Improvement of symptoms and signs of allergy
Conversion of SPT to negative 6 months from diagnosis to end of Follow-up period Improvement of symptoms and signs of allergy
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Zagazig University Faculty of Medicine
🇪🇬Zagazig, Sharkia, Egypt